Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 363

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

Open access
Cefalu, William T., Kaul, Sanjay, Gerstein, Hertzel C., Holman, Rury R., Zinman, Bernard, Skyler, Jay S., Green, Jennifer B., Buse, John B., Inzucchi, Silvio E., Leiter, Lawrence A., Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C. · 2018 · Diabetes Care

Abstract

Editors' Expert Forum convened to review the processes and challenges of CVOTs, discuss the benefits and limitations of their current designs, and weigh the merits of modifications that might improve the efficiency and clinical value of future trials. Discussion and analysis continued with the CVOT trial results released in June 2017 at the American Diabetes Association's Scientific Sessions and in September 2017 at the European Association for the Study of Diabetes scientific meeting. This article summarizes the discussion and findings to date.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dci17-0057

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Research works printed but not linked: 5

  1. Caveney E, Turner JR. White paper. A review of FDA guidance: understanding the FDA guidance on assessing cardiovascular risks for new antidiabetic therapies [Internet]. Available from http://www.quintiles.com/library/white-papers/new-fda-guidance-on-antidiabetic-therapies. Accessed 31 October 2016
  2. 10.2337/diaclin.34.4.173 · doi:10.2337/diaclin.34.4.173
  3. Intarcia Therapeutics. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes: company also reports new $75 million financing for manufacturing scale-up and inventory build for anticipated global launch of ITCA 650 [Internet]. Available from https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html. Accessed 14 February 2017
  4. Gerstein, Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide, Diabetes Obes Metab
  5. Intarcia Therapeutics. Intarcia submits new drug application (NDA) to FDA for U.S. marketing approval of ITCA 650 in type 2 diabetes [Internet]. Available from https://www.intarcia.com/media/press-releases/2016-nov-21-nda-submission.html. Accessed 10 April 2017

Cited by

See all 363

Metadata

Authors
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., Raz, I., Rosenstock, J., & Riddle, M. C.
Venue
Diabetes Care
Published
2017-12-20
Volume
41
Issue
1
Pages
14-31
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2779223875
Cited by
363
References
74
FWCI
38.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum. https://app.cochat.ai/papers/10.2337/dci17-0057
The paper
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2018). Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care. https://doi.org/10.2337/dci17-0057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.